(3) The route of its administration. (4) The general health of the patient, and in particular the condition under treatment.
(5) The element of individual idiosyncrasy (an inherited predisposition to an abnormal reaction to a drug). (6) Other substances consumed simultaneously or within a short interval of the drug which may potentiate its toxic effects. 
Nature of the drug
This determines the rate of its absorption into the body and its pharmacological effects oIn the body's metabolism together with the mode and ease of its detoxication and excretion. The ease with which a drug passes into the general circulation and thence into the eye determines the ability of systemically administered drugs to affect the eye directly. Some drugs have been thought to produce ocular side-effects indirectly by their influence on the general circulation (e.g. amaurosis from a precipitous fall in blood pressure due to the use of detensive drugs) or the blood (e.g. intraocular haemorrhages produced by anticoagulants or drugs producing aplastic anaemia, agranulocytosis, or thrombocytopenia.
Amount of the drug Toxic levels of drugs may be reached in some instances by high daily dosage and in others, where detoxication and excretion are slow, by prolonged consumption. The effect of dosage in ocular toxicity is well-illustrated in the case of the antimalarials. As a malaria suppressive, dosages of chloroquine of the order of 500 mg. weekly are used and ocular complications are rare, though corneal oedema from mepacrine was first noted in such circumstances (Chamberlain and Boles, I946; Abbey and Lawrence, 1946; Reese, I946) . In the treatment of rheumatoid arthritis, lupus erythematosus, and actinic dermatitis, doses of up to I,ooo mg. chloroquine daily are used and ocular complications have now been extensively recorded and necessitate regular ophthalmic examination of such patients.
Route of administration While it is natural in dealing with this subject to think in terms of drugs administered orally or parenterally, it must not be forgotten that topical application of drugs at a distance from the eye may allow sufficient absorption to risk ocular side-effects. The danger of absorption of toxic substances applied to burns was stressed in a leading article in the British Medical Journal of June 3, I967. Systemic argyrosis following the application of silver compounds to skin ulcers was noted in four of a large series of cases of argyrosis reviewed by Hill and Pillsbury (I939). A case of systemic and ocular ochronosis following the protracted application of carbolic acid to varicose ulcers (Beddard, I9I o) and another of toxic amblyopia from the use of iodoform for an ulcerated carcinoma of the breast (Critchett, I 898) have been reported.
The eyes are frequently involved in the generalized sensitivity reactions occurring from the topical use of drugs, particularly the antibiotics. Conversely, Gerber (1957) reported a patient who developed generalized urticaria as well as a local allergic response after the treatment of herpetic keratitis by Gifford's iodine administered topically.
Patients' general health and condition under treatment Liver and renal disease frequently affect the detoxication and excretion of drugs, allowing them to accumulate to toxic levels. In some instances, it is difficult to determine whether an ocular defect has arisen as a result of involvement with the general disease or as a toxic manifestation of a drug used in therapy. This was the cause of doubt regarding the toxicity to the optic nerve of the arsenicals, particularly tryparsamide, when used in the treatment of neurosyphilis, and of streptomycin when used in tuberculous meningitis.
Individual idiosyncrasy
Rosenheim (1 958) classified the unwanted effects of drugs as: (i) overdosage; (2) intolerance, i.e. a lower threshold to the normal pharmacological action of the drug; (3) side-effects; (4) secondary effects, i.e. indirect consequences of the primary action of the drug; (5) idiosyncrasy, i.e. an inherent, qualitatively abnormal reaction to the drug; (6) hypersensitivity, i.e. a reaction conditioned by previous exposure to the drug.
Many of the isolated reports of ocular side-effects from drugs may well be the result of individual idiosyncrasy. However, in a few instances of drug toxicity, it has been shown that the tendency to an abnormal response to a drug or group of drugs is inherited and the subject of pharmacogenetics is attracting increasing attention (Vogel, 1959 The ability of non-protein drugs to act as haptens and so sensitize the patient is responsible for much iatrogenic disease, particularly where drugs are applied topically over long periods, and this is frequently seen in the field of ophthalmic therapeutics, e.g. sensitization to topical atropine.
Results of present analysis of drugs in current use These are tabulated in the ; the drugs are classified according to the system affected, and the purpose for which they are administered.
Conclusions
All physicians must be aware of the known risks to which our patients may be exposed by the prescription of modern therapeutic agents and be constantly alert to risks as yet undiscovered or unrecorded. The collection of data regarding such possible or actual sideeffects by a central agency is already being carried out in many countries, but the evaluation of such data is by no means easy (Cahal, I968) . This was seen in the attempt to correlate ocular complications arising in women taking female sex hormones as contraceptive pills with the drugs concerned (Walsh, Clark, Thompson, and Nicholson, 1965) . We must be careful not to condemn a drug of proven usefulness unless the evidence of druginduced toxicity is unequivocal or the severity of the side-effect warrants more careful appraisal. 
